Current Liabilities decreased faster than Cardiol Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Cardiol Therapeutics Inc 's Quick Ratio to 6.16, above Cardiol Therapeutics inc average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 55 other companies have achieved higher Quick Ratio than Cardiol Therapeutics Inc in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 861, from total ranking in the third quarter 2025 at 1093.

Explain Quick Ratio?
How much Cash & cash equivalents CRDL�s has?
What are CRDL�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CRDL/financial-strength

https://api.csimarket.com/api/v1/companies/CRDL/fundamentals

https://api.csimarket.com/api/v1/companies/CRDL/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

CRDL Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	-75.16 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-26.45 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	6.16	Subscribe	Subscribe	Subscribe	Subscribe
CRDL's Total Ranking	# 861	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-41.43 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-4.79 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 56
Healthcare Sector	# 273
Overall Market	# 834

Quick Ratio Statistics
High	Average	Low
7.25	4.53	2.08
(Dec 31 2021)		(Dec 31 2024)

Financial Statements
Cardiol Therapeutics Inc 's Current Liabilities	$ 3 Millions	Visit CRDL's Balance sheet
Cardiol Therapeutics Inc 's Cash & cash equivalent	$ 16 Millions	Visit CRDL's Balance sheet
Source of CRDL's Sales		Visit CRDL's Sales by Geography

Cumulative Cardiol Therapeutics Inc 's Quick Ratio

CRDL's Quick Ratio for the trailling 12 Months

CRDL Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-40.99 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-29.15 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	4.17	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4261	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-33.08 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-7.97 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to CRDL Financial Strength Comparisons >> Go to Compare CRDL Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Cardiol Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Cardiol Therapeutics Inc 's Quick Ratio to 4.17, Quick Ratio remained below CRDL average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 154 other companies have achieved higher Quick Ratio than Cardiol Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3461 to 4261.

Explain Quick Ratio?
How much Cash & cash equivalents CRDL�s has?
What are CRDL�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 155
Healthcare Sector	# 965
Within the Market	# 4261

trailing twelve months Quick Ratio Statistics
High	Average	Low
6.07	4.61	3.79
(Dec 31 2022)		(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Maze Therapeutics Inc	15.16	$ 341.917 Millions	$ 22.556 Millions
Immunovant Inc	15.01	$ 994.525 Millions	$ 66.257 Millions
Compass Therapeutics Inc	14.96	$ 208.906 Millions	$ 13.968 Millions
Candel Therapeutics Inc	14.00	$ 119.731 Millions	$ 8.552 Millions
In8bio Inc	13.95	$ 27.092 Millions	$ 1.942 Millions
Crispr Therapeutics Ag	13.25	$ 1,975.828 Millions	$ 149.120 Millions
Tscan Therapeutics Inc	13.22	$ 152.406 Millions	$ 11.528 Millions
Eikon Therapeutics Inc	13.15	$ 335.975 Millions	$ 25.549 Millions
Precision Biosciences Inc	12.97	$ 115.585 Millions	$ 8.913 Millions
Beam Therapeutics Inc	12.85	$ 1,245.210 Millions	$ 96.935 Millions
Vaxcyte Inc	12.49	$ 1,560.959 Millions	$ 124.972 Millions
Kalaris Therapeutics Inc	12.15	$ 117.982 Millions	$ 9.714 Millions
Imagenebio Inc	12.05	$ 135.349 Millions	$ 11.234 Millions
Taysha Gene Therapies Inc	12.04	$ 319.767 Millions	$ 26.552 Millions
Engene Therapeutics Inc	11.21	$ 275.948 Millions	$ 24.609 Millions
Genenta Science S p a	10.87	$ 39.465 Millions	$ 3.630 Millions
Cullinan Therapeutics Inc	10.22	$ 377.896 Millions	$ 36.961 Millions
X4 Pharmaceuticals Inc	9.82	$ 252.998 Millions	$ 25.757 Millions
4d Molecular Therapeutics Inc	9.15	$ 402.655 Millions	$ 43.985 Millions
Prokidney Corp	9.10	$ 270.017 Millions	$ 29.671 Millions
Sab Biotherapeutics Inc	9.04	$ 96.592 Millions	$ 10.681 Millions
Denali Therapeutics Inc	8.82	$ 867.879 Millions	$ 98.351 Millions
Artiva Biotherapeutics Inc	8.25	$ 108.008 Millions	$ 13.087 Millions
Black Diamond Therapeutics Inc	8.18	$ 128.652 Millions	$ 15.731 Millions
Zura Bio Limited	8.02	$ 109.407 Millions	$ 13.647 Millions
Molecular Partners Ag	7.86	$ 104.149 Millions	$ 13.254 Millions
Aura Biosciences Inc	7.85	$ 144.241 Millions	$ 18.383 Millions
Allogene Therapeutics Inc	7.70	$ 250.210 Millions	$ 32.514 Millions
Compugen Ltd	7.67	$ 145.640 Millions	$ 18.999 Millions
Voyager Therapeutics Inc	7.40	$ 196.447 Millions	$ 26.541 Millions

Date modified: 2026-10-05T11:03:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.